CPHI Milan: 6 October 2026
Nina Bladh is attending CPHI Milan 2026!
Excited to explore the latest innovations across the pharmaceutical supply chain at the world’s leading pharma event! From ingredients to finished dosage, it’s all happening in Milan this October.
🗓️ October 6-8, 2026
📍 Fiera Milano, Italy
Let’s connect while we´re there!
5th Öresund Peptide Symposium: 24 September 2026
Our CSO Christian Kjellman presents "TCP-25: An Immunomodulatory Peptide in Phase 2/3 Development for Dysregulated Inflammation in Epidermolysis Bullosa Wounds" at the 5th Öresund Peptide Symposium at Medicon Village.
The symposium brings together the peptide community from industry and academia, and we look forward to contributing to the discussions around peptide-based drug development.
debra Care Conference: 26-29 July 2026
The 2026 debra Care Conference brings together individuals with EB, families, clinicians, researchers, and partners for four days of learning, collaboration, and connection. Held in Los Angeles July 26–29, the conference features expert-led sessions and practical insights spanning every aspect of EB care and research.
The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026
The 3rd World Congress on Rare Skin Diseases — a place to deepen knowledge, discover the latest research, and connect with people who truly care about improving life for EB patients.
The 3rd World Congress on Rare Skin Diseases 2026
01-03 July 2026
Versailles, France
BIO International Convention: 22-25 June 2026
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from around the world.
BIO International Convention
22-25 June 2026
San Diego, US
https://convention.bio.org/about-bio
EADV Symposium 2026: 07-09 May 2026
The annual EADV Symposium stands as a premier international gathering devoted to dermatology and venereology, offering a dynamic platform for exchanging knowledge, collaboration, and presenting cutting-edge research findings.
EADV Symposium 2026
07-09 May 2026
Athens, Greece
https://eadv.org/symposium/
Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.
The granted patent is broad in scope and covers both the formulation currently being used in the international clinical study STEP as well as future generations of products containing TCP-25.
TCP-25 is already protected by patents in Europe and the United States and has also been granted Orphan Drug Designation in the United States.
“A strong intellectual property position is essential for us, and this new patent provides broad protection in a strategically important market,” says Helene Hartman, CEO of Xinnate AB.
